래트 및 마우스 모델 시장 규모, 점유율, 동향 분석 리포트 : 모델·서비스별, 용도별, 최종 용도별, 지역별, 부문별 예측(2024-2030년)

Rat And Mouse Model Market Growth & Trends:

The global rat and mouse model market is anticipated to reach USD 3.58 billion by 2030 and is anticipated to expand at a CAGR of 9.0% from 2024 to 2030, according to a new report by Grand View Research, Inc. Humanized mouse and rat models are used in biological and medical research due to functional human genes, tissues, cells, and organs. In health and clinical settings, these mouse & rat prototypes are utilized to replicate the human immune system. Furthermore, humanized mouse and rat prototypes are used for basic research, evaluating the safety of large-molecule medicines, simulating some human-specific infectious diseases, along with testing the efficacy of immunotherapy approaches.

The use of mouse & rat prototypes for the identification of immunodeficiency disorders, tumors, and various other rare diseases, along with an increase in R&D activities carried out by healthcare and biotechnology companies, as well as continuous funding and interventions from governments and private sectors for mouse & rat model research, are driving the global market. Furthermore, technological advancements for developing animal models are anticipated to spur market growth. Companies are adopting advanced technologies to develop better models. For instance, in October 2023, Taconic Biosciences, a major company operating in the industry, announced the ExprssMODEL CRISPR Platform, which can advance the development and manufacturing of mouse models. This platform can eliminate the need for an expansion breeding step and saves a minimum three months in the overall study timeline. Such developments are anticipated to drive the industry's growth over the forecast period.

Furthermore, players operating in the industry are undertaking several initiatives like partnerships, collaborations, acquisitions, and mergers to strengthen their market position. For instance, in April 2023, an ingenious targeting laboratory, a provider of custom genetically modified rat, mouse, and rabbit models, partnered with Shanghai Model Organisms Center (SMOC) to distribute SMOC's validated off-the-shelf mouse models in Europe and North America. Such collaborations are expected to increase the accessibility of animal models, which can drive market growth in the coming years.

Rat And Mouse Model Market Report Highlights:

• The models segment dominated the model and service segment with a revenue share of 88.6% in 2023, owing to the availability of different types of rats and animal models.
• The services segment is expected to grow at the fastest CAGR over the forecast period due to the increasing focus of industry participants on offering numerous services like cryopreservation, breeding, validation, phenotyping, husbandry and rederivation, among others.
• Based on application, the cancer segment dominated the market in 2023. On the other hand, the genetic diseases segment is expected to witness the fastest growth over the forecast period.
• North America region dominated the market owing to factors such as the presence of key market players like Inotiv, Charles River Laboratories, Ozgene Pty Ltd, Taconic Biosciences and the growth in pharmaceutical as well as research sectors in this region.
• Asia Pacific is expected to register the fastest growth over the forecast period due to several companies expanding their presence in Asia Pacific countries like Japan.
• Major market players operating in the global rat and mouse models market include Charles River Laboratories, The Jackson Laboratory, Cyagen, genOway, Inotiv, Janvier Labs, Taconic Biosciences, Inc., Biomedical Research Models (Biomere), Hera Biolabs, Kind Lab, and Ozgene Pty Ltd. among others

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Model and Service
  • 1.2.2. Application
  • 1.2.3. End-use
  • 1.2.4. Regional scope
  • 1.2.5. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
    • 1.4.5.1. Data for Primary Interviews in North America
    • 1.4.5.2. Data for primary interviews in Europe
    • 1.4.5.3. Data for primary interviews in Asia Pacific
    • 1.4.5.4. Data for Primary Interviews in Latin America
    • 1.4.5.5. Data for Primary Interviews in MEA
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Model and Service Outlook
  • 2.2.2. End-use outlook
  • 2.2.3. Application outlook
  • 2.2.4. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Rat and Mouse Model Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Rise in adoption of personalized & precision medicine and increasing demand of rat & mouse models.
    • 3.2.1.2. Application of genome editing tools for generation of rodent models
    • 3.2.1.3. Increase in the number of research activities involving the use of rat and mouse models.
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. Ethical issues pertaining to the use of animals for research.
    • 3.2.2.2. Rise in adoption of alternative animal models for biomedical research
• 3.3. Rat and Mouse Model Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic Landscape
  • 3.3.3. COVID-19 Impact Analysis

Chapter 4. Rat and Mouse Model Market: Model and Service Estimates & Trend Analysis

• 4.1. Model and Service Market Share, 2023 & 2030
• 4.2. Segment Dashboard
• 4.3. Global Rat and Mouse Model Market by Model and Service Outlook
• 4.4. Model & Service Market Size & Forecasts and Trend Analysis, 2018 to 2030 for the following
  • 4.4.1. Model
    • 4.4.1.1. Model Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.1.2. Inbred
    • 4.4.1.2.1. Inbred Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.1.2.2. Knockout
    • 4.4.1.2.2.1. Knockout Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.1.2.3. Knock-in
    • 4.4.1.2.3.1. Knock-in Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.1.2.4. Others
    • 4.4.1.2.4.1. Others Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.1.3. Outbred
    • 4.4.1.3.1. Outbred Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.1.3.2. Knockout
    • 4.4.1.3.2.1. Knockout Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.1.3.3. Knock-in
    • 4.4.1.3.3.1. Knock-in Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.1.3.4. Others
    • 4.4.1.3.4.1. Others Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.2. Service
    • 4.4.2.1. Service Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.2.2. Cryopreservation
    • 4.4.2.2.1. Cryopreservation Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.2.3. Breeding
    • 4.4.2.3.1. Breeding Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.2.4. Rederivation
    • 4.4.2.4.1. Rederivation Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.2.5. Genetic Testing
    • 4.4.2.5.1. Genetic Testing Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.2.6. Quarantine Depending
    • 4.4.2.6.1. Quarantine Depending Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.2.7. Others
    • 4.4.2.7.1. Others Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Rat and Mouse Model Market: Application Estimates & Trend Analysis

• 5.1. Application Market Share, 2023 & 2030
• 5.2. Segment Dashboard
• 5.3. Global Rat and Mouse Model Market by Application Outlook
• 5.4. Application Market Size & Forecasts and Trend Analysis, 2018 to 2030 for the following
  • 5.4.1. Application Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.4.2. Cardiovascular diseases
    • 5.4.2.1. Cardiovascular Diseases Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.4.3. Genetic Diseases
    • 5.4.3.1. Genetic Diseases Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.4.4. Cancer
    • 5.4.4.1. Cancer Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.4.5. Infectious Diseases
    • 5.4.5.1. Infectious Diseases Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.5.1.1. COVID-19
    • 5.4.5.1.1.1. COVID-19 Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.5.1.2. Others
    • 5.4.5.1.2.1. Others Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.4.6. Transplantation
    • 5.4.6.1. Transplantation Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.4.7. Others
    • 5.4.7.1. Others Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Rat and Mouse Model Market: End-use Estimates & Trend Analysis

• 6.1. End-use Market Share, 2023 & 2030
• 6.2. Segment Dashboard
• 6.3. Global Rat and Mouse Model Market by End-use Outlook
• 6.4. End-use Market Size & Forecasts and Trend Analysis, 2018 to 2030 for the following
  • 6.4.1. Pharmaceutical & Biotechnology companies
    • 6.4.1.1. Pharmaceutical & Biotechnology Companies Market estimates and forecasts 2018 to 2030 (USD million)
  • 6.4.2. Academic and Research Facilities
    • 6.4.2.1. Academic and Research Facilities Market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.3. Contract Research & Manufacturing Organizations
    • 6.4.3.1. Contract Research & Manufacturing Organizations Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Rat and Mouse Model Market: Regional Estimates & Trend Analysis

• 7.1. Regional Market Share Analysis, 2023 & 2030
• 7.2. Regional Market Dashboard
• 7.3. Global Regional Market Snapshot
• 7.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030
• 7.5. North America
  • 7.5.1. U.S.
    • 7.5.1.1. Key country dynamics
    • 7.5.1.2. Regulatory framework
    • 7.5.1.3. Competitive scenario
    • 7.5.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.2. Canada
    • 7.5.2.1. Key country dynamics
    • 7.5.2.2. Regulatory framework
    • 7.5.2.3. Competitive scenario
    • 7.5.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
• 7.6. Europe
  • 7.6.1. UK
    • 7.6.1.1. Key country dynamics
    • 7.6.1.2. Regulatory framework
    • 7.6.1.3. Competitive scenario
    • 7.6.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.2. Germany
    • 7.6.2.1. Key country dynamics
    • 7.6.2.2. Regulatory framework
    • 7.6.2.3. Competitive scenario
    • 7.6.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.3. France
    • 7.6.3.1. Key country dynamics
    • 7.6.3.2. Regulatory framework
    • 7.6.3.3. Competitive scenario
    • 7.6.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.4. Italy
    • 7.6.4.1. Key country dynamics
    • 7.6.4.2. Regulatory framework
    • 7.6.4.3. Competitive scenario
    • 7.6.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.5. Spain
    • 7.6.5.1. Key country dynamics
    • 7.6.5.2. Regulatory framework
    • 7.6.5.3. Competitive scenario
    • 7.6.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.6. Norway
    • 7.6.6.1. Key country dynamics
    • 7.6.6.2. Regulatory framework
    • 7.6.6.3. Competitive scenario
    • 7.6.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.7. Sweden
    • 7.6.7.1. Key country dynamics
    • 7.6.7.2. Regulatory framework
    • 7.6.7.3. Competitive scenario
    • 7.6.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.8. Denmark
    • 7.6.8.1. Key country dynamics
    • 7.6.8.2. Regulatory framework
    • 7.6.8.3. Competitive scenario
    • 7.6.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
• 7.7. Asia Pacific
  • 7.7.1. Japan
    • 7.7.1.1. Key country dynamics
    • 7.7.1.2. Regulatory framework
    • 7.7.1.3. Competitive scenario
    • 7.7.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.2. China
    • 7.7.2.1. Key Country Dynamics
    • 7.7.2.2. Regulatory framework
    • 7.7.2.3. Competitive scenario
    • 7.7.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.3. India
    • 7.7.3.1. Key country dynamics
    • 7.7.3.2. Regulatory framework
    • 7.7.3.3. Competitive scenario
    • 7.7.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.4. Australia
    • 7.7.4.1. Key country dynamics
    • 7.7.4.2. Regulatory framework
    • 7.7.4.3. Competitive scenario
    • 7.7.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.5. South Korea
    • 7.7.5.1. Key country dynamics
    • 7.7.5.2. Regulatory framework
    • 7.7.5.3. Competitive scenario
    • 7.7.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.6. Thailand
    • 7.7.6.1. Key country dynamics
    • 7.7.6.2. Regulatory framework
    • 7.7.6.3. Competitive scenario
    • 7.7.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
• 7.8. Latin America
  • 7.8.1. Brazil
    • 7.8.1.1. Key country dynamics
    • 7.8.1.2. Regulatory framework
    • 7.8.1.3. Competitive scenario
    • 7.8.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.8.2. Mexico
    • 7.8.2.1. Key country dynamics
    • 7.8.2.2. Regulatory framework
    • 7.8.2.3. Competitive scenario
    • 7.8.2.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.8.3. Argentina
    • 7.8.3.1. Key country dynamics
    • 7.8.3.2. Regulatory framework
    • 7.8.3.3. Competitive scenario
    • 7.8.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
• 7.9. MEA
  • 7.9.1. South Africa
    • 7.9.1.1. Key country dynamics
    • 7.9.1.2. Regulatory framework
    • 7.9.1.3. Competitive scenario
    • 7.9.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.9.2. Saudi Arabia
    • 7.9.2.1. Key country dynamics
    • 7.9.2.2. Regulatory framework
    • 7.9.2.3. Competitive scenario
    • 7.9.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.9.3. UAE
    • 7.9.3.1. Key country dynamics
    • 7.9.3.2. Regulatory framework
    • 7.9.3.3. Competitive scenario
    • 7.9.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.9.4. Kuwait
    • 7.9.4.1. Key country dynamics
    • 7.9.4.2. Regulatory framework
    • 7.9.4.3. Competitive scenario
    • 7.9.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Recent Developments & Impact Analysis, By Key Market Participants
• 8.2. Company/Competition Categorization
• 8.3. Vendor Landscape
  • 8.3.1. List of key distributors and channel partners
  • 8.3.2. Key customers
  • 8.3.3. Key company market share analysis, 2023
  • 8.3.4. Charles River Laboratories
    • 8.3.4.1. Company overview
    • 8.3.4.2. Financial performance
    • 8.3.4.3. Product benchmarking
    • 8.3.4.4. Strategic initiatives
  • 8.3.5. The Jackson Laboratory
    • 8.3.5.1. Company overview
    • 8.3.5.2. Financial performance
    • 8.3.5.3. Product benchmarking
    • 8.3.5.4. Strategic initiatives
  • 8.3.6. Cyagen
    • 8.3.6.1. Company overview
    • 8.3.6.2. Financial performance
    • 8.3.6.3. Product benchmarking
    • 8.3.6.4. Strategic initiatives
  • 8.3.7. genOway
    • 8.3.7.1. Company overview
    • 8.3.7.2. Financial performance
    • 8.3.7.3. Product benchmarking
    • 8.3.7.4. Strategic initiatives
  • 8.3.8. Inotiv
    • 8.3.8.1. Company overview
    • 8.3.8.2. Financial performance
    • 8.3.8.3. Product benchmarking
    • 8.3.8.4. Strategic initiatives
  • 8.3.9. Janvier Labs
    • 8.3.9.1. Company overview
    • 8.3.9.2. Financial performance
    • 8.3.9.3. Product benchmarking
    • 8.3.9.4. Strategic initiatives
  • 8.3.10. Taconic Biosciences, Inc.
    • 8.3.10.1. Company overview
    • 8.3.10.2. Financial performance
    • 8.3.10.3. Product benchmarking
    • 8.3.10.4. Strategic initiatives
  • 8.3.11. Biomedical Research Models (Biomere)
    • 8.3.11.1. Company overview
    • 8.3.11.2. Financial performance
    • 8.3.11.3. Product benchmarking
    • 8.3.11.4. Strategic initiatives
  • 8.3.12. Hera Biolabs
    • 8.3.12.1. Company overview
    • 8.3.12.2. Financial performance
    • 8.3.12.3. Product benchmarking
    • 8.3.12.4. Strategic initiatives
  • 8.3.13. Kind Lab
    • 8.3.13.1. Company overview
    • 8.3.13.2. Financial performance
    • 8.3.13.3. Product benchmarking
    • 8.3.13.4. Strategic initiatives
  • 8.3.14. Ozgene Pty Ltd
    • 8.3.14.1. Company overview
    • 8.3.14.2. Financial performance
    • 8.3.14.3. Product benchmarking
    • 8.3.14.4. Strategic initiatives